Pfizer stock declines 3.45% as COVID-19 product sales drop and overbought conditions emerge

Traders Union
All News
Financial News
Pfizer slides 3.45% to $25.75 today

Highlights

Pfizer reported fourth-quarter earnings and revenue above analyst estimates but maintained a cautious outlook due to declining COVID-19 sales and exclusivity losses on key drugs.
The company is focusing on its obesity drug pipeline, highlighting a $10 billion acquisition of Metsera and mid-stage trial results showing about 13% weight loss.
Technically, Pfizer trades at $25.75 just above MA-20 and MA-50, with dynamic support near $25.83 and resistance likely at the $26.00 level.

Upbeat earnings and obesity pipeline offset COVID drag and exclusivity loss

Pfizer reported fourth-quarter earnings that exceeded analyst expectations, with revenue also surpassing average estimates. The company reaffirmed a challenging outlook due to declining COVID-19 product sales, reduced pricing from supply agreements with the U.S. government, and the loss of exclusivity on key medications. To address these challenges, Pfizer is emphasizing its obesity drug pipeline and announced a $10 billion acquisition of Metsera; recent mid-stage trial results from this pipeline showed approximately 13% weight loss and were notable for influencing shares post-announcement.

Momentum signals remain bullish as overbought risk emerges

Pfizer is exhibiting a bullish bias as the price remains above key moving averages (MA-20, MA-50, MA-200). The Ichimoku Kijun at $25.83 is the closest dynamic support, while resistance sits near the MA-50 and the $26.00 round level. Momentum indicators such as MACD continue to signal a buy, and ADX shows building but not yet strong trend strength. However, oscillators including RSI (62.2), Stochastic RSI, and CCI indicate overbought conditions; Bull/Bear Power and the Awesome Oscillator are aligned to the upside, highlighting ongoing buyer dominance.

Sideways bias favored as upside breakout probability rises

In the next five trading days, Pfizer is expected to remain within a $25.60 to $26.20 volatility band relative to current levels, consistent with typical blue-chip behavior. The upside probability is high (over 80%), while the chance of a decrease is low in the very short term. The baseline scenario anticipates sideways movement just above recently reclaimed support, with the bullish case materializing if price breaks above $26.20 toward $26.50, and a bearish move possible below $25.60 that could trigger renewed downside momentum.

Viktoras Karapetjanc, Traders Union expert, sees Pfizer maintaining a bullish structure after its earnings beat and recent acquisition news. He notes the price action confirms positive sentiment, supported by strong fundamentals and macro stability. The expert believes limited COVID-19 revenues are already reflected in the price, while the obesity drug pipeline provides a new catalyst. Short-term volatility is likely capped to the upside. "I expect Pfizer to hold above key supports, with a strong chance for a breakout if momentum persists above $26.20."

Previously it was reported that Pfizer is exhibiting strong bullish momentum, trading well above its short-, medium-, and long-term moving averages, with technical indicators such as MACD and RSI remaining upbeat despite overbought readings in some oscillators. Current support is seen near $26.15 with resistance around $26.24 and $27, as the stock is expected to maintain a sideways-to-bullish bias in the near term amid low volatility and a high likelihood of further upward movement.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.